

# Use of Bleomycin in the Sclerotherapy of Lymphatic Malformations for Pediatric Patients

NCT06437158

---

|            |                     |
|------------|---------------------|
| Status     | RECRUITING          |
| Phase      | Phase 2             |
| Sponsor    | West China Hospital |
| Enrollment | 200 participants    |

## Key Eligibility Criteria

---

### Inclusion (3)

- Male or female participants less than 14 years of age at the time of informed consent/assent form was signed.
- Participants whose parents have voluntarily given written consent and participants who provided assent (if applicable) after the study has been explained to them.
- Participants with LMs of all sites measured and confirmed via imaging at screening, with rapid progression, resulting in obvious symptoms or dysfunction, which could not be radically resected and could be treated by sclerotherapy.

### Exclusion (4)

- Penicillin allergy.
- Vascular tumors or combined vascular malformations.
- Participants who may have had surgical or sclerotherapy treatment by other hardeners.
- LMs growing slowly, without obvious symptoms or dysfunction, which does not need to be treated prematurely.

## Locations (1 total)

---

West China Hospital of Sichuan University, Chengdu, Sichuan, China